Moreover, we showed that blocking nucleoside transport increased the efficacy of DHODH inhibitors in the presence of physiological concentrations of uridine, suggesting a therapeutic strategy to overcome plasma uridine-dependent resistance to DHODH-targeting drugs in cancer patients. This evidence concerns the gene DHODH and cancer.